AstraZeneca has got off to a strong start in 2020, with the FDA granting a fast review for its diabetes drug Farxiga in heart failure and China approving Lokelma for hyperkalemia.
Link:https://www.mobihealthnews.com/content/how-central-east-africas-tech-renaissance-shaping-its-healthcare-future
Aging is caused by the deterioration of various cellular organelles and physiological processes. The pathways elements that are affected during ageing include insulin resistance, changes in body composition, decline in growth hormone, insulin-like growth factor, and sex steroids.
Artios Pharma, a U.K. based company in Cambridge, has raised $84 million to take DNA damage response (DDR) programs to the next level of clinical proof of concept.
In a major breakthrough in cancer research, a team of scientists from the University of Toronto, The Institute of Cancer Research, London, The Netherlands Cancer Institute and the University of Bern have discovered how cells repair damaged strands of DNA. They revealed a brand new protein complex in cells that protect broken DNA ends and causes its repair, in their study published in Nature on Wednesday.
The immunotherapy drug was approved for lung cancer patients with no chance for surgery whose cancer had not yet spread to other parts of the body.
Tagworks Pharmaceuticals, based at Radboud University Medical Center, have developed a novel technique for the targeted delivery of ADCs to treat tumors. By the controlled 'click-to-release' of the chemotherapy drug from its tumor-binding carrier, the treatment would reach the right location.
According to reports, the biotechnology company Abpro has rescheduled its $96 million IPO, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year.
Based on the recommendation of the DMC, the trial will continue to evaluate progression-free survival (PFS), which is a secondary endpoint. Results from KEYNOTE-042 will be presented at an upcoming medical meeting and submitted to regulatory authorities worldwide.
Novartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna® (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.